Dilute aPTT and PTT LA in Lupus Anticoagulant Testing
The dilute aPTT (activated partial thromboplastin time) serves as the LA-sensitive screening test with low phospholipid content to detect lupus anticoagulant, while the PTT LA (confirmatory test) uses high phospholipid concentration to confirm that the prolongation is specifically due to phospholipid-dependent inhibition rather than other causes.
The Three-Step Testing Algorithm
Lupus anticoagulant testing follows a mandatory three-step process 1:
Step 1: Screening Test (Dilute aPTT)
- The dilute aPTT uses low phospholipid concentration and silica as activator, making it highly sensitive to LA antibodies 1, 2
- If the screening test shows prolonged clotting time beyond the 99th percentile cutoff, proceed to mixing and confirmatory steps
- Both dRVVT and LA-sensitive aPTT must be performed in parallel - omitting either test increases underdiagnosis risk by up to 55% in triple aPL-positive samples 1
Step 2: Mixing Test
- Mix patient plasma 1:1 with pooled normal plasma (PNP) without preincubation 2
- If the prolongation persists despite mixing, this suggests an inhibitor (LA) rather than factor deficiency
- A negative mixing test (correction to normal) essentially rules out LA
Step 3: Confirmatory Test (PTT LA)
- The PTT LA confirmatory test adds high phospholipid concentration to the same aPTT system 2
- Key principle: If LA antibodies are present, adding excess phospholipids will shorten or "correct" the clotting time because the antibodies become saturated
- Calculate percentage correction: [(screen - confirm)/screen] × 100
- LA is confirmed if the percentage correction exceeds the locally established cutoff (typically mean of normal controls) 2
Why This Two-Test Approach Matters
The dilute aPTT detects LA through phospholipid dependency, but prolonged aPTT alone could indicate:
- Lupus anticoagulant (phospholipid-dependent inhibitor)
- Coagulation factor deficiencies (VIII, IX, XI)
- Heparin contamination
- Specific factor inhibitors
The confirmatory step with high phospholipids distinguishes LA from these other causes - only phospholipid-dependent inhibitors will correct with added phospholipids 2.
Critical Pitfalls to Avoid
Anticoagulant Interference
- Never test during anticoagulation if avoidable - DOACs, warfarin, and heparin cause false positives/negatives 1
- If testing on DOACs is unavoidable, use DOAC removal agents (activated charcoal) and compare pre/post-treatment results 1
- For heparin: The three-step method remains reliable if anti-Xa activity is within therapeutic range, as dRVVT reagents contain heparin neutralizers 1
Sample Quality
- Requires double centrifugation to achieve platelet-poor plasma (<10,000 platelets/μL) 2
- Residual platelets release phospholipids that neutralize LA, causing false negatives
Single Test Limitations
- Using aPTT alone misses 31% of APS patients 1
- Different LA antibodies have varying sensitivities to different phospholipid systems
- Always combine aPTT-based testing with dRVVT for optimal detection 1
Interpretation Framework
A positive LA result requires:
- Prolonged screening test (dilute aPTT)
- Positive mixing test (prolongation persists)
- Positive confirmatory test (correction with high phospholipids) 1
The pattern of "positive screen, negative mixing, positive confirm" can only be detected by performing all three steps simultaneously on samples with prolonged screening tests 1.
Repeat testing after ≥12 weeks is mandatory before confirming persistent LA positivity for APS diagnosis 2.